PIERRE FABRE MEDICAMENT
Bormioli & Pierre Fabre develop 100% recycled PET packaging for mouthwash - European Pharmaceutical Manufacturer
Adjuvant pembrolizumab extends DFS in resected early-stage non-small cell lung cancer
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Xavier FOUILLAND - Direction de la Performance - Pierre Fabre Group | LinkedIn
Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre | Fierce Biotech
STUDY: L00070 IN 309 F0
PIERRE-FABRE | Business Wire
Pharmaceutical Laboratory : Recruitment | Pierre Fabre
TCT-ASTCT-CIBMTR 2022: Multicenter, Open-Label, Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease ...
Pierre Fabre and Roche extend pact on companion diagnostic for cancer | Fierce Biotech
Summer Academy Meeting : 2014 Advance Program
ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
Pierre Fabre combo follows up US approval with EC nod
Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024 :: Scrip
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Articles about Atara Biotherapeutics, Inc. | page 2
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Agenda - 100% Radio
